Report of Foreign Issuer (6-k)
August 27 2020 - 7:11AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of August 2020
001-36203
(Commission
File Number)
CAN-FITE
BIOPHARMA LTD.
(Exact
name of Registrant as specified in its charter)
10
Bareket Street
Kiryat
Matalon, P.O. Box 7537
Petach-Tikva
4951778, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F þ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
____
This
Report on Form 6-K (including Exhibits 99.1 and 99.2 and the text under the heading “Financial Results”, the accompanying interim condensed consolidated
financial statements and “Forward Looking Statements” in the press release in Exhibit 99.3) is hereby incorporated by reference into the registrant’s
Registration Statements on Form S-8 (File No. 333-227753) and Form F-3 (File Nos. 333-195124, 333-236064, 333-209037 and
333-220644), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents
or reports subsequently filed or furnished.
On August 27, 2020, Can-Fite
BioPharma Ltd. (the “Company”) issued a press release announcing financial results for the six months ended June
30, 2020 and updates on its drug development programs. In addition, on the same day, the Company issued unaudited interim
condensed consolidated financial statements as of June 30, 2020. Attached hereto and incorporated by reference
herein are the following exhibits:
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Can-Fite BioPharma Ltd.
|
|
|
|
Date: August 27, 2020
|
By:
|
/s/
Pnina Fishman
|
|
|
Pnina Fishman
|
|
|
Chief Executive Officer
|
3
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024